In our experiments, this conclusion is supported by various lines of evidence: (i) overexpression of c-FLIPL, a natural caspase-8 inhibitor, in ovarian cancer cell lines resulted in a protection against the pro-apoptotic effects elicited by LBW242 alone or in combination with TRAIL; (ii) addition of a synthetic cell-permeable caspase-8 inhibitor, zIETD-fmk, to ovarian cancer cells resulted in a marked inhibition of LBW242+TRAIL-induced apoptosis. The gene discussed is CFLAR; the disease is ovarian carcinoma.